Loading...
PT Kalbe Farma Tbk.
PTKFY•PNK
Healthcare
Drug Manufacturers - General
$18.45
$0.00(0.00%)
PT Kalbe Farma Tbk. (PTKFY) Financial Performance & Income Statement Overview
Review PT Kalbe Farma Tbk.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
7.16%
↑ 7.16%
Operating Income Growth
12.03%
↑ 12.03%
Net Income Growth
17.13%
↑ 17.13%
Operating Cash Flow Growth
67.94%
↑ 67.94%
Operating Margin
12.71%
↑ 12.71%
Gross Margin
39.87%
↑ 39.87%
Net Profit Margin
10.15%
↑ 10.15%
ROE
14.88%
↑ 14.88%
ROIC
16.16%
↑ 16.16%
PT Kalbe Farma Tbk. (PTKFY) Income Statement & Financial Overview
Review PT Kalbe Farma Tbk.'s (PTKFY) income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $8845.37B | $8389.01B | $7910.51B | $7965.22B |
| Cost of Revenue | $5169.10B | $4948.95B | $4858.03B | $4934.09B |
| Gross Profit | $3676.27B | $3440.07B | $3052.48B | $3031.13B |
| Gross Profit Ratio | $0.42 | $0.41 | $0.39 | $0.38 |
| R&D Expenses | $103.54B | $154.09B | $78.56B | $100.84B |
| SG&A Expenses | $1303.08B | $1187.82B | $1335.37B | $1092.87B |
| Operating Expenses | $2300.39B | $2358.44B | $3052.48B | $1975.13B |
| Total Costs & Expenses | $7469.49B | $7307.39B | $7216.43B | $6909.22B |
| Interest Income | $50.44B | $49.70B | $53.94B | $35.31B |
| Interest Expense | $13.03B | $18.75B | $12.73B | $22.71B |
| Depreciation & Amortization | $86.13B | $204.20B | $84.60B | $186.49B |
| EBITDA | $1524.80B | $1224.18B | $818.32B | $1309.06B |
| EBITDA Ratio | $0.17 | $0.15 | $0.10 | $0.16 |
| Operating Income | $1375.88B | $1081.63B | $694.08B | $1056.007B |
| Operating Income Ratio | $0.16 | $0.13 | $0.09 | $0.13 |
| Other Income/Expenses (Net) | $53.39B | $45.21B | $30.53B | $36.97B |
| Income Before Tax | $1429.26B | $1126.83B | $724.61B | $1099.86B |
| Income Before Tax Ratio | $0.16 | $0.13 | $0.09 | $0.14 |
| Income Tax Expense | $318.81B | $276.60B | $159.09B | $256.62B |
| Net Income | $1076.77B | $862.26B | $573.28B | $847.54B |
| Net Income Ratio | $0.12 | $0.10 | $0.07 | $0.11 |
| EPS | $23.57 | $18.67 | $12.42 | $18.33 |
| Diluted EPS | $23.57 | $18.67 | $12.42 | $18.33 |
| Weighted Avg Shares Outstanding | $45.69B | $45.95B | $46.15B | $46.24B |
| Weighted Avg Shares Outstanding (Diluted) | $45.69B | $45.95B | $46.15B | $46.24B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan